Media headlines about CONMED Corporation (NASDAQ:CNMD) have been trending somewhat positive on Friday, according to Accern Sentiment Analysis. The research group rates the sentiment of news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. CONMED Corporation earned a media sentiment score of 0.08 on Accern’s scale. Accern also gave media coverage about the medical technology company an impact score of 44.7410250993653 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the headlines that may have impacted Accern Sentiment Analysis’s rankings:
- ETFs with exposure to CONMED Corp. : November 16, 2017 (finance.yahoo.com)
- CONMED Corporation (CNMD) Expected to Announce Quarterly Sales of $211.29 Million (americanbankingnews.com)
- CONMED Corporation (CNMD) Receives Average Recommendation of “Hold” from Brokerages (americanbankingnews.com)
- CONMED Corporation (CNMD) Expected to Post Earnings of $0.68 Per Share (americanbankingnews.com)
- CONMED Corporation (CNMD) Stock Rating Upgraded by Zacks Investment Research (americanbankingnews.com)
Several equities analysts have issued reports on CNMD shares. BidaskClub cut shares of CONMED Corporation from a “sell” rating to a “strong sell” rating in a research note on Sunday, August 20th. Zacks Investment Research cut shares of CONMED Corporation from a “hold” rating to a “sell” rating in a research note on Monday, November 6th. KeyCorp reissued a “hold” rating on shares of CONMED Corporation in a research note on Friday, November 3rd. Piper Jaffray Companies reissued a “hold” rating and issued a $46.00 price objective on shares of CONMED Corporation in a research note on Friday, November 3rd. Finally, Needham & Company LLC restated a “buy” rating and set a $57.00 target price on shares of CONMED Corporation in a research report on Friday, September 1st. One analyst has rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the company. CONMED Corporation has an average rating of “Hold” and a consensus price target of $50.33.
Shares of CONMED Corporation (NASDAQ CNMD) opened at $51.92 on Friday. The company has a market cap of $1,405.91, a price-to-earnings ratio of 28.76, a price-to-earnings-growth ratio of 3.18 and a beta of 0.66. CONMED Corporation has a 1 year low of $39.74 and a 1 year high of $54.47. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.49 and a current ratio of 2.56.
CONMED Corporation (NASDAQ:CNMD) last issued its earnings results on Thursday, November 2nd. The medical technology company reported $0.42 EPS for the quarter, topping the consensus estimate of $0.41 by $0.01. The company had revenue of $190.10 million for the quarter, compared to analyst estimates of $187.13 million. CONMED Corporation had a net margin of 1.99% and a return on equity of 8.40%. The business’s revenue was up 2.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.41 EPS. sell-side analysts predict that CONMED Corporation will post 1.86 earnings per share for the current fiscal year.
In related news, EVP Luke A. Pomilio sold 10,020 shares of the business’s stock in a transaction dated Friday, November 3rd. The shares were sold at an average price of $53.57, for a total value of $536,771.40. Following the sale, the executive vice president now directly owns 44,472 shares in the company, valued at approximately $2,382,365.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Luke A. Pomilio sold 29,363 shares of the business’s stock in a transaction dated Thursday, November 9th. The stock was sold at an average price of $50.70, for a total transaction of $1,488,704.10. Following the completion of the sale, the executive vice president now owns 45,486 shares in the company, valued at $2,306,140.20. The disclosure for this sale can be found here. Insiders sold a total of 51,812 shares of company stock worth $2,654,756 over the last quarter. Insiders own 2.62% of the company’s stock.
CONMED Corporation Company Profile
CONMED Corporation is a medical technology company. The Company is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. The Company provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology.
Receive News & Ratings for CONMED Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED Corporation and related companies with MarketBeat.com's FREE daily email newsletter.